期刊文献+

硼替佐米皮下注射治疗多发性骨髓瘤患者给药时的护理 被引量:1

原文传递
导出
摘要 目的探讨硼替佐米皮下注射治疗多发性骨髓瘤给药时的护理方法及措施。方法 2013年3月-2014年1月,对26例多发性骨髓瘤患者应用硼替佐米皮下注射联合地塞米松的方案进行治疗,给药时做好心理护理,掌握正确的给药方法,做到准确给药,严防不良反应的发生。结果 26例患者中,5例完全缓解,18例部分缓解,3例病情进展,用药过程中未发生与护理相关的不良反应。结论硼替佐米皮下注射操作方便,患者痛感小,通过正确的给药方法,准确的给药剂量,最大限度的发挥了药物的疗效,提高了患者的治疗效果。
作者 谭怡
出处 《华西医学》 CAS 2014年第4期637-639,共3页 West China Medical Journal
  • 相关文献

参考文献7

  • 1孙菁,周进祝.内科学[M].6版.北京:科学出版社,2003:797-798.
  • 2Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma[J]. N Engl J Med, 2003, 348(26): 2609-2617.
  • 3Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two dose of bortezomib in relapsed or refractory myeloma[J]. Br J Haematol, 2004, 127(2): 165-172.
  • 4刘志刚,牛挺,向兵,常红,何川,李建军,黄杰,谢莉萍,朱焕玲,贾永前,刘霆.万珂为主化疗方案治疗多发性骨髓瘤的临床研究[J].四川大学学报(医学版),2009,40(2):358-360. 被引量:16
  • 5曾科,刘志刚,杨金荣,侯理,羊裔明,刘霆,牛挺.硼替佐米皮下注射联合自体造血干细胞移植治疗POEMS综合征一例报告并文献复习[J].中华血液学杂志,2013,34(6):550-552. 被引量:7
  • 6Moreau P, Coiteux V, Hulin C, et al. Prospective comparison of subcutaneous vs intravenous administration ofbortezomib in patients with multiple myeloma[J]. Haematologica, 2008, 93:1908-1911.
  • 7Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study[J]. Lancet Oncol, 2011, 12(5): 431-440.

二级参考文献30

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin,2007,57(1) :43-60.
  • 2Sirohi B, Powles R. Multiple myeloma. Lancet, 2004; 363 (9412) :875-887.
  • 3Durie BL, Harousseau JH, Miguel JS, et al. International uniform response criteria for multiple myeloma. Luekemia, 2006 , 20(9) : 1467-1473.
  • 4National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in OneologyTM Multiple Myeloma (V. 3. 2008). Available at http://www. nccn. org/ professionals/physician_gle/PDF/myeloma. pdf.
  • 5Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet,2006 367(9513) :825-831.
  • 6Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer,2004,4(5) :349-360.
  • 7Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasomc inhibitor PS-341. Blood, 2003 ,101 (4) : 1530-1534.
  • 8Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial ceils. Cancer Res, 2006 , 66 (1) : 184-191.
  • 9Manochakian R, Miller K, Chanan-Khan A. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. The Oncologist,2007,12(8) :978-990.
  • 10Mateos MV, Hernandez .IM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multieenter phase 1/2 study. Blood,2006,108(7):2165-2172.

共引文献22

同被引文献17

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部